Stocks in play: NeonMind Biosciences Inc.

Announced today it has released preclinical data demonstrating the efficacy of psilocybin in reducing weight gain in obese subjects. In previous preclinical studies, NeonMind has shown efficacy in reducing weight gain in healthy subjects with normal weight. This latest study suggests a broader therapeutic potential of psilocybin in weight management and supports the current development track of NeonMind's drug candidates. The data from NeonMind's preclinical models revealed a novel finding for its drug candidates: the ability to target visceral fat. Increased visceral fat is linked to poorer cardiometabolic health and reduction in this type of fat is important in weight loss and better overall health outcomes. Additional findings from the preclinical models in obese subjects include: Statistical significance compared to the control group for both absolute and relative weight gain; Efficacy seen within days of administration; Reduced food consumption compared to control group; No safety signals. NeonMind Biosciences Inc. shares C.NEON are trading unchanged at $0.06.